Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals

Objective(s):HIV/hepatitis C virus (HCV) coinfection causes accelerated liver disease compared to HCV monoinfection, and only 30–60% of HIV/HCV-coinfected individuals respond to HCV therapy with pegylated interferon and ribavirin. There are currently no biomarkers that predict treatment response in these coinfected patients. Design:We investigated whether there is an association between HCV treatment response and SNPs of apoptosis-related genes during HIV/HCV coinfection. Method:Genomic DNA from 53 HIV/HCV-coinfected individuals was analyzed for 82 SNPs of 10 apoptosis-related genes. Results:We found that the presence of the rs4242392 SNP in tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), which encodes for tumor necrosis factor-related apoptosis-inducing ligand receptor 1, predicts poor outcome to HCV therapy, in HIV/HCV-co-infected patients [odds ratio 5.91 (95% confidence interval 1.63–21.38, P = 0.007)]. Conclusion:The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients.

[1]  Hong Yang,et al.  Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. , 2010, International journal of epidemiology.

[2]  Hans-Gustaf Ljunggren,et al.  Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. , 2010, Gastroenterology.

[3]  M. Major,et al.  Clearance of hepatitis C in chimpanzees is associated with intrahepatic T‐cell perforin expression during the late acute phase , 2010, Journal of viral hepatitis.

[4]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[5]  M. Dallas,et al.  Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence , 2009, Proceedings of the National Academy of Sciences.

[6]  A. Badley,et al.  The TRAIL to viral pathogenesis: the good, the bad and the ugly. , 2009, Current molecular medicine.

[7]  William M. Lee,et al.  DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. , 2008, Journal of hepatology.

[8]  Yu Shyr,et al.  The prediction of interferon treatment effects based on time series microarray gene expression profiles , 2008, Journal of Translational Medicine.

[9]  S. Chokshi,et al.  Viral clearance or persistence after acute hepatitis C infection: interim results from a prospective study. , 2008, Medicina.

[10]  A. Bahnassy,et al.  Immunomodulators, sFas and Fas‐L as potential noninvasive predictors of IFN treatment in patients with HCV genotype‐4 , 2007, Journal of viral hepatitis.

[11]  V. Soriano,et al.  Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. , 2007, AIDS.

[12]  J. Benítez,et al.  Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. , 2007, Cancer biomarkers : section A of Disease markers.

[13]  Alison A Motsinger,et al.  Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. , 2006, The Journal of infectious diseases.

[14]  H. Brenner,et al.  Death Receptor 4 Variants and Colorectal Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[15]  J. Peiris,et al.  Functional Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Production by Avian Influenza Virus–Infected Macrophages , 2006, The Journal of infectious diseases.

[16]  J. Lifson,et al.  CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. , 2005, Blood.

[17]  M. Manns,et al.  Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake , 2005, Gut.

[18]  S. Kikuchi,et al.  TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis , 2005, Journal of Neuroimmunology.

[19]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[20]  T. Wienker,et al.  Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis , 2004, Journal of Neuroimmunology.

[21]  V. Soriano,et al.  Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients , 2003 .

[22]  V. Soriano,et al.  Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. , 2003, AIDS.

[23]  A. Badley,et al.  Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L , 2001, Journal of Virology.

[24]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[25]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  G. Barber.  Host defense, viruses and apoptosis , 2001, Cell Death and Differentiation.

[27]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  J. Goedert,et al.  Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. , 1994, Blood.